MEA Region Has Relatively Stable Quarter

BMI View: The better-regulated markets of the Gulf Cooperation Council (GCC), South Africa and Israel will remain the most rewarding and least risky for drugmakers operating in the Middle East and Africa (MEA). However, these markets are rapidly approaching maturity and are expected to grow only in the mid-to-high single digits. As pharmaceutical companies look to enter markets with higher potential, they should turn their attention first to the Gulf Levant and then North Africa, where population demographics, the regulatory framework and macroeconomic factors will facilitate

To read the full article, please choose one of the following options: